 REDWOOD CITY, CA ACCESSWIRE July 6, 2021 Avinger, Inc. NASDAQ:AVGR, a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease PAD, today announced the submission of a 510k application to the U.S. Food Drug Administration FDA for a new Pantheris clinical indication for the treatment of in-stent restenosis ISR in the lower extremity arteries. Highlighting the importance of this submission, Jeff Soinski, Avingers President and CEO commented, We are extremely pleased with this milestone and the initial clinical data generated from the INSIGHT trial that supports the 510k submission. 